Precigen (NASDAQ:PGEN) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Precigen (NASDAQ:PGEN) in a research report released on Friday morning,Benzinga reports. The firm currently has a $4.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Precigen’s FY2026 earnings at $0.01 EPS, FY2027 earnings at $0.22 EPS and FY2028 earnings at $0.39 EPS.

Several other research firms have also commented on PGEN. JMP Securities lowered their price objective on shares of Precigen from $14.00 to $7.00 and set a “market outperform” rating for the company in a research note on Thursday, August 15th. StockNews.com raised Precigen to a “sell” rating in a research report on Thursday, August 1st. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $7.00.

Precigen Trading Down 3.4 %

Shares of NASDAQ PGEN opened at $0.79 on Friday. The stock has a market capitalization of $232.01 million, a PE ratio of -1.44 and a beta of 1.68. Precigen has a twelve month low of $0.78 and a twelve month high of $1.93. The stock has a fifty day simple moving average of $0.92 and a 200-day simple moving average of $1.24.

Hedge Funds Weigh In On Precigen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PGEN. Vanguard Group Inc. raised its stake in Precigen by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 6,768,234 shares of the biotechnology company’s stock worth $9,814,000 after acquiring an additional 19,875 shares in the last quarter. Iridian Asset Management LLC CT increased its position in Precigen by 82.5% during the third quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock worth $3,576,000 after buying an additional 1,706,815 shares during the period. Geode Capital Management LLC grew its position in Precigen by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after purchasing an additional 149,829 shares during the last quarter. State Street Corp increased its stake in Precigen by 1.0% in the third quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock valued at $2,720,000 after purchasing an additional 29,253 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Precigen by 11.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock valued at $1,158,000 after buying an additional 127,467 shares during the last quarter. 33.51% of the stock is owned by institutional investors and hedge funds.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.